Sign up Australia
Proactive Investors - Run By Investors For Investors

Roto-Gro International joins ASX list of cannabis-tech companies

Roto-Gro produces an automated hydroponic growing system.
Roto-Gro International joins ASX list of cannabis-tech companies
Australia legalised medical cannabis on 1 November 2016

Roto-Gro International (ASX:RGI), a Canadian cannabis-tech company has been admitted to the ASX, and has become the latest player to join the list of cannabis based companies on the ASX.

Roto-Gro produces a fully automated rotary hydroponic system (a method of growing plants without soil) which can be used to grow up to 420 cannabis plants.

Australia legalised medical cannabis on 1 November 2016.

The new market in Australia is a significant opportunity for peripheral industries, specifically those that help grow, extract and distribute cannabis products.

Roto-Gro will also target the Canadian market and other markets that allow the lawful production of cannabis.

The Roto-Gro System, in which plants rotate around a single light source and receive nutrients from a stand-alone reservoir, uses about half the energy of traditional growing systems and 80% less water.

The unit could be used for growing other plants in addition to its utility for cannabis growers.

The Roto-Gro System was designed and manufactured in Canada in late 2006 and has undergone continuous improvement since that date.

Between 2007 and 2012, about 600 units have been sold worldwide by Canadian distributor NutriLife Products.

Last week, cannabis medicines company Auscann Group Holdings (ASX:AC8) was admitted to the ASX.

It follows a rush of medical cannabis stocks to join the ASX including Zelda Therapeutics (ASX:ZLD), MGC Pharmaceuticals (ASX:MXC) and Creso Pharma (ASX:CPH).





Register here to be notified of future RGI Company articles
View full RGI profile View Profile

Roto-Gro International Ltd Timeline

Related Articles

test tubes filled with blood
November 03 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
scientist looking through a microscope
November 01 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use